Hussman Strategic Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-25,200
| Closed | -$2.79M | – | 266 |
|
|
2025
Q1 | $2.79M | Buy |
25,200
+16,800
| +200% | +$1.86M | 0.68% | 37 |
|
|
2024
Q4 | $1.15M | Sell |
8,400
-23,100
| -73% | -$3.15M | 0.34% | 120 |
|
|
2024
Q3 | $3.63M | Buy |
31,500
+6,300
| +25% | +$726K | 0.89% | 17 |
|
|
2024
Q2 | $3.47M | Buy |
25,200
+14,700
| +140% | +$2.02M | 0.96% | 12 |
|
|
2024
Q1 | $1.45M | Hold |
10,500
| – | – | 0.34% | 112 |
|
|
2023
Q4 | $1.38M | Sell |
10,500
-17,900
| -63% | -$2.36M | 0.31% | 132 |
|
|
2023
Q3 | $3.2M | Sell |
28,400
-8,000
| -22% | -$900K | 0.61% | 42 |
|
|
2023
Q2 | $3.43M | Sell |
36,400
-10,100
| -22% | -$952K | 0.63% | 30 |
|
|
2023
Q1 | $4.71M | Buy |
46,500
+20,500
| +79% | +$2.08M | 0.74% | 20 |
|
|
2022
Q4 | $3.11M | Sell |
26,000
-5,200
| -17% | -$621K | 0.51% | 75 |
|
|
2022
Q3 | $3.31M | Hold |
31,200
| – | – | 0.57% | 47 |
|
|
2022
Q2 | $3.04M | Hold |
31,200
| – | – | 0.52% | 55 |
|
|
2022
Q1 | $2.93M | Buy |
31,200
+20,800
| +200% | +$1.95M | 0.57% | 55 |
|
|
2021
Q4 | $886K | Sell |
10,400
-5,100
| -33% | -$434K | 0.19% | 168 |
|
|
2021
Q3 | $1.49M | Hold |
15,500
| – | – | 0.33% | 121 |
|
|
2021
Q2 | $1.51M | Buy |
+15,500
| New | +$1.51M | 0.31% | 127 |
|
|
2020
Q4 | – | Sell |
-10,000
| Closed | -$962K | – | 299 |
|
|
2020
Q3 | $962K | Hold |
10,000
| – | – | 0.25% | 159 |
|
|
2020
Q2 | $1.22M | Sell |
10,000
-5,000
| -33% | -$610K | 0.31% | 126 |
|
|
2020
Q1 | $1.3M | Buy |
+15,000
| New | +$1.3M | 0.35% | 116 |
|
|
2019
Q2 | – | Sell |
-10,000
| Closed | -$881K | – | 231 |
|
|
2019
Q1 | $881K | Hold |
10,000
| – | – | 0.22% | 162 |
|
|
2018
Q4 | $714K | Buy |
+10,000
| New | +$714K | 0.17% | 177 |
|